An LC/MS/MS Method for Quantifying Testosterone and Dehydroepiandrosterone Sulfate in Four Different Serum Samples during a Single Run

Shunsuke FUJIMURA*, Takenori ITO*, Shoujiro OGAWA*, Takayuki ISHIGE***, Shoichi NISHIMOTO-KUSUNOSE*, and Tatsuya HIGASHI*,†**

** Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda 278-8510, Japan*

*** Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, 1 Sanzo, Gakuen-cho, Fukuyama 729-0292, Japan*

**** Division of Laboratory Medicine, Chiba University Hospital, 1-8-1 Inohana, Chuo, Chiba 260-8677, Japan*

† To whom correspondence should be addressed.

E-mail: higashi@rs.tus.ac.jp

Abstract

Simultaneous measurement of the circulating testosterone (TS) and dehydroepiandrosterone sulfate (DHEAS) is deemed to be helpful for the assessment of men's health. Liquid chromatography/electrospray ionization-tandem mass spectrometry (LC/ESI-MS/MS) is the most reliable methodology for this purpose, however, it has room for improvement in analysis throughput. In this study, a quadruplicate of the Girard reagents was used to develop an LC/ESI-MS/MS method capable of quantifying TS and DHEAS in four different serum samples in a single run. The four serum samples were separately pretreated, derivatized with one of four Girard reagents, then combined. The LC/ESI-MS/MS analysis of the combined sample provided the androgen concentrations of four serum samples in parallel. The method had practical measuring ranges, in which good precision and accuracy, and negligible matrix effects were verified. The speed-up capability of the developed method was evaluated through the analysis of 10 batches of serum samples (total 40 samples); the method saved a 60% post-pretreatment analysis time compared to the non-derivatization method for 40 samples.

Keywords Sample-multiplexing, Derivatization, Androgen, High throughput, LC/ESI-MS/MS, Girard reagent

Introduction

Testosterone (TS) is the primary androgen essential to the development and maintenance of male characteristics. It is well known that the abnormal production of TS is associated with hypogonadism (impaired production), and testis and prostate tumors (over-production). Recent studies have also demonstrated that the TS deficiency might cause many disorders including diabetes,¹ cardiovascular diseases,² osteoporosis,³ and depression.⁴ The measurement of the circulating TS is indispensable for assessment of the androgen status in men, and consequently, in the diagnosis and treatment of these disorders.

Dehydroepiandrosterone (DHEA) is an adrenal androgen and most (over 99%) of DHEA circulates in the blood as the sulfated form, *i.e.*, DHEA sulfate (DHEAS). Although it is still debated whether DHEAS in itself has specific biological functions, many studies have shown that the decline in the circulating DHEAS level is associated with diabetes,⁵ cardiovascular diseases,⁶ osteoporosis,⁷ and depression.⁸ Thus, common disorders are found in patients with the TS deficiency and those with low circulating DHEAS concentrations. Therefore, it is expected that the measurement of the serum/plasma DHEAS together with TS proves more helpful for the assessment of men's health.

In most clinical laboratories, commercially-available immunoassay-based test kits are used for both the TS and DHEAS measurements. However, immunoassay occasionally has a problem of inaccuracy of the measured results due to interference from structurally similar steroids (cross-reactivity of the used antibodies).^{9, 10} Furthermore, the simultaneous measurement of TS and

DHEAS is impossible using the immunoassay kits. Liquid chromatography/electrospray ionization-tandem mass spectrometry (LC/ESI-MS/MS) can provide more reliable results due to its high specificity based on the LC separation and MS/MS discrimination. LC/ESI-MS/MS also has the capability of the simultaneous quantification of TS and DHEAS in a single injection. However, LC/ESI-MS/MS has a challenge to overcome for routine clinical laboratory use; it is inferior to immunoassay regarding the analysis throughput because LC/ESI-MS/MS generally analyzes one sample at a time. As one of the solutions for this challenge, Kishi *et al.* reported a novel multiplex LC/MS system, in which multiple liquid chromatographs and one mass spectrometer were connected; in this system, an individual chromatogram for each sample was extracted from the mixed chromatograms of the multiple samples by the frequency division multiplexing technique.¹¹ Although this system will be put to practical use in the future, currently, the derivatization-based sample-multiplexing can be a more practical solution to enhance the analysis throughput of LC/ESI-MS/MS.¹² In the sample-multiplexing strategy, multiple samples are derivatized with multiple well-designed reagents, then the derivatized samples are combined and injected into the LC/ESI-MS/MS. Because the multiple sample quantification is achieved during a single LC/ESI-MS/MS run, the total LC/ESI-MS/MS run time can be considerably reduced. Several successful examples of the derivatization-based sample-multiplexing strategy have been reported for the quantification of various low molecular-weight compounds including a vitamin D metabolite,¹³ fatty acids,¹⁴ sphingolipids,¹⁵ and chiral carboxylic acids¹⁶ in biological samples. This strategy was also applied to the steroid quantification.^{17–20} A set of structurally analogous derivatization reagents

with different masses is indispensable for the sample-multiplexing strategy; the resulting derivatives closely elute from the LC, show similar ESI-MS/MS behaviors, and are separately quantified by different selected reaction monitoring (SRM) transitions. Both TS and DHEAS have a carbonyl group, therefore, Girard reagents can be used to derivatize these androgens. We have reported the sample-quadruplex LC/ESI-MS/MS method for the high throughput quantification of serum DHEAS using the Girard reagents.¹⁹ It is of significance to expand this strategy to the quantification of the most clinically-important androgen, TS, for the assessment of androgen status.

Based on this background information, the objective of this study was to develop and validate an LC/ESI-MS/MS method capable of quantifying TS and DHEAS in four different serum samples during a single run. This method employed a quadruplicate of the Girard reagents, *i.e.*, Girard T (GT), Girard P (GP) and their isotopologues [$^2\text{H}_3$ -GT (*d*GT) and $^2\text{H}_5$ -GP (*d*GP)] (Fig. 1). To demonstrate the advantage of the derivatization-based sample-multiplexing strategy, the analysis time was compared between the developed method and a non-derivatization LC/ESI-MS/MS method, which analyzed only one sample per injection.

Experimental

Materials and chemicals

TS and $^2\text{H}_3$ -TS [internal standard (IS) for TS] were obtained from Tokyo Chemicals Industry

(Tokyo, Japan) and Sigma-Aldrich Japan (Tokyo), respectively. DHEAS and $^2\text{H}_4$ -DHEAS (IS for DHEAS) were synthesized in our laboratories and the same as those used in a previous study.¹⁹ Stock solutions were prepared by dissolving a precisely-weighed quantity of the steroids with ethanol. Working solutions were prepared by serial dilutions of the stock solutions; 1.6, 3.2, 6.4, 16, 32 and 64 ng mL⁻¹ for TS, 1.0, 2.0, 4.0, 10, 20 and 40 µg mL⁻¹ for DHEAS, 32 ng mL⁻¹ for $^2\text{H}_3$ -TS and 20 µg mL⁻¹ for $^2\text{H}_4$ -DHEAS. GT and GP were the products of Tokyo Chemical Industry. *d*GT and *d*GP were synthesized in our laboratories.^{19, 21} An Oasis[®] HLB solid-phase extraction (SPE) cartridge (30 mg adsorbent; Waters, Milford, MA) was used to purify the serum samples. All other reagents and solvents were of analytical grade or LC/MS grade.

Serum samples

The serum samples were collected from apparently healthy adult male volunteers ($n = 40$) at the Chiba University Hospital (Chiba, Japan) and stored at -30°C until used. The experimental procedures were approved by the Ethics Committees of Tokyo University of Science and Chiba University. Written forms of informed consent were obtained from all the volunteers.

Pretreatment procedure

The serum sample (40 µL) was dropped into ethanol (60 µL) containing the ISs ($^2\text{H}_3$ -TS; 320 pg and $^2\text{H}_4$ -DHEAS; 200 ng), vortex-mixed for 30 s, then centrifuged at $2,000\times g$ for 5 min. The supernatant was diluted with water (0.9 mL), then loaded on an Oasis[®] HLB cartridge. After

sequential washing the cartridge with water (1 mL) and 45% (v/v) methanol (1 mL), the steroids were eluted with methanol (1 mL). The solvent was evaporated off under a N₂ gas stream, then the residue was dissolved in methanol-acetic acid (9:1, v/v, 50 µL) containing one of the reagents (GT, *d*GT, GP or *d*GP, 20 µg). This reaction mixture was left in a dry bath incubator at 80°C for 15 min. Four serum samples derivatized with different reagents were mixed and the solvent was evaporated. The residue was re-dissolved in the mobile phase (60 µL). The procedure to determine the recovery rates of TS, DHEAS and their ISs during the purification steps is described in the Supporting Information.

LC/ESI-MS/MS

The LC/ESI-MS/MS quantification was performed by a Shimadzu LCMS-8030 triple quadrupole mass spectrometer with a Shimadzu LC-30AD chromatograph (Kyoto, Japan) and LabSolutions software (version 5.53 SP3, Shimadzu) for the system control and data processing. The derivatized androgens were separated on an ACQUITY UPLC BEH C18 column (1.7 µm, 100 × 2.1 mm i.d., Waters) with a mobile phase of methanol-10 mM ammonium formate-formic acid (45:55:0.1, v/v/v) at 40°C. The flow rate was 0.3 mL min⁻¹ and the injection volume was 15 µL. The ESI-MS/MS parameters are described in the Supporting Information. The SRM transitions for the respective compounds are summarized in Table 1.

Calibration curves

The serum was treated with activated charcoal to remove the androgens,¹⁹ then used as the

surrogate matrix for the calibration curves. This surrogate matrix (40 μL) was dropped into ethanol containing TS (16, 32, 64, 160, 320 or 640 pg; corresponding to 0.40, 0.80, 1.6, 4.0, 8.0 or 16 ng mL^{-1} , respectively, 6 points), DHEAS (10, 20, 40, 100, 200 or 400 ng; corresponding to 0.25, 0.50, 1.0, 2.5, 5.0 or 10 $\mu\text{g mL}^{-1}$, respectively, 6 points) and ISs ($^2\text{H}_3$ -TS; 320 pg and $^2\text{H}_4$ -DHEAS; 200 ng), then treated in the same way as previously described. The four samples derivatized with the different reagents were mixed and injected into the LC/ESI-MS/MS. The peak area ratios (derivatized TS/ $^2\text{H}_3$ -TS or DHEAS/ $^2\text{H}_4$ -DHEAS, y) were plotted versus the concentrations [TS (ng mL^{-1}) or DHEAS ($\mu\text{g mL}^{-1}$), x] with a $1/x$ weighting to construct the calibration curves.

Matrix effects

The matrix effects were assessed by the post-extraction addition experiment.²² The matrix effects were determined as the ratios of the peak areas in the serum samples to those in the standard samples. The detailed procedure is contained in the Supporting Information.

Precision and accuracy

Five repetitions of the measurements were carried out for three pooled serum samples with different androgen concentrations at one day (intra-assay) and for five consecutive days (inter-assay) to test the assay precision. The assay accuracy was evaluated based on the analytical recoveries, which were the ratios (%) of the measured concentrations to the nominal concentrations. The detailed procedures are contained in the Supporting Information.

Non-derivatization method for quantification of serum TS and DHEAS

The non-derivatization LC/ESI-MS/MS method for the determination of the serum TS and DHEAS was also developed and validated in our laboratories. This method analyzed one sample during a single LC/ESI-MS/MS run. The details including the validation data (Table S3) are described in the Supporting Information.

Results and Discussion

LC/ESI-MS/MS behavior of derivatized androgens

The derivatization was a key component to achieve the quantification of TS and DHEAS in four different samples during a single LC/ESI-MS/MS run.¹² A quadruplicate of the Girard reagents, *i.e.*, GT, *d*GT, GP and *d*GP, was used for this purpose because of their structural similarity, high reactivity to ketosteroids and ready availability. It is well known that the 3-oxo-4-ene steroids, such as TS, are readily derivatized with the Girard reagents.^{17, 23} Although the keto group of DHEAS (at the 17-position) is less reactive than that of TS (at the 3-position), our previous study verified that the derivatization using any Girard reagents almost quantitatively proceeded to DHEAS under the stated conditions¹⁹ (Fig. 1). The derivatization allowed not only TS but also DHEAS to be sensitively detected in the positive-ion mode and all the resulting derivatives gave molecular cations ($[M]^+$) as the

base peaks. The product ions giving the greatest signal-to-noise ratios (S/N) during the SRM were $[M-X]^+$ and $[M-X-H_2SO_4]^+$ for the derivatized TSs and DHEASs, respectively, where X was the terminal charged moiety (trimethylammonium or pyridinium). The elimination of the terminal charged moieties is the well-known fragmentation for the ketosteroids derivatized with the Girard reagents.^{17, 19, 23, 24} Thus, the characteristic product ions containing the steroid skeletons (*i.e.*, analyte-specific ions) were obtained from both androgens, which enhanced the assay specificity. The SRM transitions described in Table 1 were used for the quantification of TS and DHEAS in the serum, and showed no overlap between the respective derivatives, including the derivatized ISs.

The derivatization of ketosteroids with Girard reagents usually produces the *E*- and *Z*-isomeric mixtures.^{17, 21} For each derivatized TS, two peaks corresponding to these isomers appeared on the chromatogram and the slower-eluting peak, which was the major isomer but not identified as the *E*- or *Z*-isomer, was used for the quantification. In contrast, all the derivatized DHEASs gave single peaks under the stated LC conditions. We found that an ACQUITY UPLC BEH C18 column (1.7 μ m, 100 $\times$ 2.1 mm i.d.) combined with a mobile phase of methanol-10 mM ammonium formate-formic acid (45:55:0.1, v/v/v) gave good peak shapes and satisfactory separation from coexisting substances for the short retention times (t_{RS}) (Table 1). All the derivatized TSs and DHEASs eluted within 5 min, therefore, a short LC/ESI-MS/MS run was consequently achieved even for the simultaneous analysis of four serum samples.

Specificity

To examine the assay specificity, the major endogenous androgens were analyzed under the stated LC/ESI-MS/MS conditions. Among the tested steroids, the derivatized androstenedione, 5 α -dihydrotestosterone and epietiocholanolone closely eluted to the derivatized TSs, and the derivatized epiandrosterone sulfate closely eluted to the derivatized DHEASs (Table S1, Supporting Information). However, only negligibly small or no peaks were detected from these derivatized steroids when the SRM transitions set for the derivatized TSs, DHEASs and their ISs were operated. For other steroids including DHEA, androsterone, epiandrosterone, etiocholanolone, androsterone sulfate, etiocholanolone sulfate and epietiocholanolone sulfate, their derivatives were completely separated by LC from the derivatized TSs or DHEASs. Considering these results, we concluded that endogenous androgens do not interfere with the TS and DHEAS quantification in our LC/ESI-MS/MS platform.

Pretreatment procedure and matrix effects

The serum samples were purified by deproteinization and SPE prior to the derivatization. Because DHEAS occurs in serum at a relatively high concentration (over several hundred nanograms mL⁻¹ for healthy male adults), the saturation of the mass analyzer occurred when an amount of DHEAS injected into LC/ESI-MS/MS was beyond its capacity; the saturation of the mass analyzer narrowed the linear dynamic range, leading to a poor accuracy. To avoid this occurrence, the recovery of DHEAS during the SPE was purposely lowered by washing the cartridge with 45% methanol. On the other hand, TS (several nanograms mL⁻¹ in serum for healthy male adults) was

mostly retained on the cartridge during this washing step. The remaining TS, DHEAS and their ISs were then recovered with methanol. Eventually, the recovery rates during the entire purification steps were 74.3 ± 2.0 , 77.5 ± 3.5 , 8.9 ± 0.7 and $9.1 \pm 0.4\%$ (mean $\pm$ SD, $n = 3$) for TS, $^2\text{H}_3$ -TS, DHEAS and $^2\text{H}_4$ -DHEAS, respectively. Thus, the desired results were produced, and there were no significant differences in the recovery rates between the analytes and their ISs. Chromatograms obtained from a batch are shown in Fig. 2. Sixteen peaks corresponding to the derivatized TSs, DHEASs and ISs were observed without any interfering peaks.

Because the serum extract per analysis multiplied four-fold in our procedure to achieve the simultaneous measurement of four samples, we were concerned about the increased matrix effects (ion suppression by the serum matrix). However, no significant matrix effects were found as shown in Table 2; only approximately 5% and 10% decreases in the peak areas for the derivatized TSs and DHEASs, respectively, were found in the serum samples compared to the standard samples.

Calibration curves and lower limits of quantification

A good linearity ($r^2 \geq 0.995$) and reproducibility [relative standard deviations (RSDs) in slopes, $\leq 2.3\%$] were found in all the calibration curves, which were independently constructed using five different surrogate matrices, within the ranges of $0.40\text{--}16 \text{ ng mL}^{-1}$ for TS and $0.25\text{--}10 \text{ }\mu\text{g mL}^{-1}$ for DHEAS (Table 3).

At the lowest points on the calibration curves, the RSDs of the measured concentrations in five replicates did not exceed 20% for both TS ($\leq 12.1\%$) and DHEAS ($\leq 11.8\%$) (Table 3). Furthermore,

the relative errors defined by the equation of $[(\text{measured concentration} - \text{nominal concentration}) / \text{nominal concentration}] \times 100 (\%)$ ranged from -2.5 to 1.0% for TS and from -4.8 to -2.0% for DHEAS. Based on these results, the lower limits of quantitation (LLOQs) were the same as the lowest calibration points (0.40 ng mL^{-1} for TS and $0.25 \text{ }\mu\text{g mL}^{-1}$ for DHEAS).

Precision and accuracy

The acceptable intra-assay ($n = 5$) and inter-assay ($n = 5$) RSDs ($\leq 8.8\%$ for TS and $\leq 8.5\%$ for DHEAS), and the analytical recovery rates ($96.1\text{--}108.1\%$ for TS and $93.2\text{--}106.9\%$ for DHEAS) were verified for every derivative of both androgens (Table S2, Supporting Information). Therefore, the proposed method was judged precise and accurate. Furthermore, the method yielded almost identical measured values for the same serum samples whichever reagent was used; every reagent effectively and coequally served for quantification of the serum TS and DHEAS (Table S2).

Applicability and advantage of sample-quadruplex method

Forty serum samples from apparently healthy adult males were divided at random into 10 batches, then analyzed by the developed method. The measured concentrations were $2.17\text{--}6.75 \text{ ng mL}^{-1}$ ($3.42 \pm 0.95 \text{ ng mL}^{-1}$, mean $\pm$ SD) and $1.04\text{--}3.75 \text{ }\mu\text{g mL}^{-1}$ ($1.99 \pm 0.65 \text{ }\mu\text{g mL}^{-1}$) for TS and DHEAS, respectively. These values were in good agreement with the concentrations in the literatures; $2.69\text{--}8.74 \text{ ng mL}^{-1}$ and $1.99\text{--}7.84 \text{ ng mL}^{-1}$ for TS^{25, 26} and $0.34\text{--}3.70 \text{ }\mu\text{g/mL}$ ²⁷ for DHEAS. These results prove that the developed method works well for clinical sample analysis. However, no

patients' samples were unfortunately available in this study, therefore, some experiments may be needed to more clearly show the clinical applicability of the method.

To demonstrate the advantage of the sample-quadruplex method in the analysis throughput, it was compared with the non-derivatization LC/ESI-MS/MS method, which analyzed one sample during a single LC/ESI-MS/MS run. The concentrations determined by the non-derivatization method (x) and the quadruplex method (y) were almost identical for both TS and DHEAS (Wilcoxon signed-rank test, $P < 0.01$) and well correlated with each other ($y = 0.990x + 0.038$, $r^2 = 0.946$ for TS and $y = 0.987x + 0.031$, $r^2 = 0.960$ for DHEAS, Pearson's correlation coefficient test, $P < 0.01$) (Fig. S1, Supporting Information). In the non-derivatization method, it took 7 min for one sample (one LC/ESI-MS/MS run), therefore, 280 min were needed after the sample purification (deproteinization and SPE) for the 40 samples. On the other hand, the sample-quadruplex method employed the derivatization, therefore, an extra 45 min were required for this derivatization (operation and reaction time) prior to the LC/ESI-MS/MS analysis. However, the LC/ESI-MS/MS run time could be reduced to 60 min (6 min per run $\times$ 10 runs, 4 samples per run) by the sample-multiplexing. Therefore, 105 min in total were required for the 40 samples after the SPE. This result means that the quadruplex method was able to save the post-pretreatment analysis time by more than 60% for the 40 samples.

Conclusion

A derivatization-based LC/ESI-MS/MS method was developed to quantify TS and DHEAS in four different serum samples during a single run. The quadruplicate of Girard reagents was the important factor in order to analyze the four samples in parallel. The derivatized androgens eluted from LC with short t_{RS} and provided intense and characteristic ions suitable for the SRM detection operating in the positive-ion mode. The control of the recovery rate of DHEAS (in $\mu\text{g mL}^{-1}$ level) during the SPE prevented the mass analyzer from being saturated, and the quantification of DHEAS together with TS (in ng mL^{-1} level) was eventually achieved. The developed method significantly saved the analysis time (60% decrease compared to the non-derivatization method for 40 samples) without increased matrix effects and decreased precision and accuracy. The method was almost unaffected by the endogenous androgens. This well-characterized method will prove helpful in the assessment of the androgen status in men, and furthermore, in the diagnosis and treatment for androgen-related disorders.

Acknowledgments

This study was supported in part by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 20K06990.

Supporting Information

The ESI-MS/MS parameters, method validation procedures and data, and non-derivatization method are available free of charge on the Web at <http://www.jasc.or.jp/analsci/>.

References

1. M. W. O'Reilly, M. Glisic, B. Kumarendran, A. Subramanian, K. N. Manolopoulos, A. A. Tahrani, D. Keerthy, T. Muka, K. A. Toulis, W. Hanif, G. N. Thomas, O. H. Franco, W. Arlt, and K. Nirantharakumar, *Clin. Endocrinol.*, **2019**, *90*, 145.
2. C. Ohlsson, E. Barrett-Connor, S. Bhasin, E. Orwoll, F. Labrie, M. K. Karlsson, Ö. Ljunggren, L. Vandenput, D. Mellström, and Å. Tivesten, *J. Am. Coll. Cardiol.*, **2011**, *58*, 1674.
3. T. S. Tran, J. R. Center, M. J. Seibel, J. A. Eisman, M. M. Kushnir, A. L. Rockwood, and T. V. Nguyen, *Clin. Chem.*, **2015**, *61*, 1182.
4. Z. Chen, X. Shen, K. Tian, Y. Liu, S. Xiong, Q. Yu, L. Dai, Y. Shi, R. Zhang, R. Zeng, Q. Wan, C. Xiong, and Y. Zhou, *J. Int. Med. Res.*, **2020**, *48*, 300060520941715. <https://doi.org/10.1177/0300060520941715>
5. L. Liu, M. Wang, X. Yang, M. Bi, L. Na, Y. Niu, Y. Li, and C. Sun, *Clin. Chem.*, **2013**, *59*, 1338.
6. Y. Moriyama, H. Yasue, M. Yoshimura, Y. Mizuno, K. Nishiyama, R. Tsunoda, H. Kawano, K. Kugiyama, H. Ogawa, Y. Saito, and K. Nakao, *J. Clin. Endocrinol. Metab.*, **2000**, *85*, 1834.
7. D. Lee, H. Kim, S. H. Ahn, S. H. Lee, S. J. Bae, E. H. Kim, H. K. Kim, J. W. Choe, B. J. Kim, and J. M. Koh, *Clin. Endocrinol.*, **2015**, *83*, 173.
8. T. Michikawa, Y. Nishiwaki, M. Nakano, S. Iwasawa, M. Yamada, K. Asakura, N. Yoshioka, E. Kuwahara, and T. Takebayashi, *Am. J. Geriatr. Psychiatry*, **2013**, *21*, 1154.
9. Ž. Debeljak, I. Marković, J. Pavela, I. Lukić, D. Mandić, S. Mandić, V. Horvat, and V. Šerić, *Biochem. Med.*, **2020**, *30*, 030701. <https://doi.org/10.11613/BM.2020.030701>
10. K.-I. Ohno, T. Hasegawa, T. Tamura, H. Utsumi, and K. Yamashita, *Anal. Sci.*, **2018**, *34*, 1017.
11. H. Kishi, T. Kumazaki, S. Kitagawa, and H. Ohtani, *Analyst*, **2019**, *144*, 2922.
12. T. Higashi and S. Ogawa, *J. Chromatogr. A*, **2020**, *1634*, 461679. <https://doi.org/10.1016/j.chroma.2020.461679>
13. S. Ogawa, H. Kittaka, A. Nakata, K. Komatsu, T. Sugiura, M. Satoh, F. Nomura, and T. Higashi, *J. Pharm. Biomed. Anal.*, **2017**, *136*, 126.
14. V. K. Narayana, V. M. Tomatis, T. Wang, D. Kvaskoff, and F. A. Meunier, *Chem. Biol.*, **2015**,

- 22, 1552.
15. S. E. Chen, S. Zhu, J. Hu, J. Sun, Z. Zheng, X. E. Zhao, and H. Liu, *Anal. Chim. Acta*, **2020**, *1124*, 40.
 16. J. Zheng, S. J. Zheng, C. B. Qi, D. M. Wu, and Y. Q. Feng, *Anal. Chem.*, **2019**, *91*, 11440.
 17. M. Kamemura, M. Yokota, S. Ogawa, T. Sugiura, and T. Higashi, *J. Chromatogr. B*, **2020**, *1146*, 122117. <https://doi.org/10.1016/j.jchromb.2020.122117>
 18. A. Jo, S. Koyagi, W. Hobo, Otani S, S. Ogawa, and T. Higashi, *Anal. Sci.*, **2020**, *36*, 1099.
 19. S. Aso, S. Ogawa, S. Nishimoto-Kusunose, M. Satoh, T. Ishige, F. Nomura, and T. Higashi, *Biomed. Chromatogr.*, **2021**, *35*, e5027. <https://doi.org/10.1002/bmc.5027>
 20. J. D. Colletti, M. M. Redor-Goldman, A. E. Pomperada, A. K. Ghoshal, W. W. Wu, M. J. McPhaul, and N. J. Clarke, *Clin. Chem.*, **2020**, *66*, 1181.
 21. T. Higashi, M. Akaishi, M. Yokota, T. Suzuki, S. Ogawa, Y. Sugiura, T. Nishikawa, K. Nishimoto, and M. Suematsu, *J. Chromatogr. B*, **2018**, *1092*, 106.
 22. R. Thakare, Y. S. Chhonker, N. Gautam, J. A. Alamoudi, Y. Alnouti, *J. Pharm. Biomed. Anal.*, **2016**, *128*, 426.
 23. A. J. Frey, Q. Wang, C. Busch, D. Feldman, L. Bottalico, C. A. Mesaros, I. A. Blair, A. Vachani, and N. W. Snyder, *Steroids*, **2016**, *116*, 60.
 24. P. J. Crick, J. Aponte, T. W. Bentley, I. Matthews, Y. Wang, and W. J. Griffiths, *Biochem. Biophys. Res. Commun.*, **2014**, *446*, 756.
 25. G. Sun, J. Xue, L. Li, X. Li, Y. Cui, B. Qiao, D. Wei, and H. Li, *Mol. Med. Rep.*, **2020**, *22*, 1576.
 26. M. M. Kushnir, A. L. Rockwood, W. L. Roberts, E. G. Pattison, A. M. Bunker, R. L. Fitzgerald, A. W. Meikle, *Clin. Chem.*, **2006**, *52*, 120.
 27. G. Eisenhofer, M. Peitzsch, D. Kaden, K. Langton, C. Pamporaki, J. Masjkur, G. Tsatsaronis, A. Mangelis, T. A. Williams, M. Reincke, J. W. M. Lenders, and S. R. Bornstein, *Clin. Chim. Acta*, **2017**, *470*, 115.

Table 1 SRM transitions (precursor and product ions) and t_{RS}

Steroid	Derivative	Precursor ion (m/z)	Product ion (m/z)	t_R /min
TS	GT	402.3	343.2	(3.2) ^a and 4.2
	<i>d</i> GT	405.3	343.2	(3.2) ^a and 4.2
	GP	422.3	343.2	(3.4) ^a and 4.4
	<i>d</i> GP	427.3	343.2	(3.4) ^a and 4.4
² H ₃ -TS (IS)	GT	405.3	346.2	(3.2) ^a and 4.2
	<i>d</i> GT	408.3	346.2	(3.2) ^a and 4.2
	GP	425.3	346.2	(3.4) ^a and 4.4
	<i>d</i> GP	430.3	346.2	(3.4) ^a and 4.4
DHEAS	GT	482.3	325.3	1.7
	<i>d</i> GT	485.3	325.3	1.7
	GP	502.3	325.3	1.9
	<i>d</i> GP	507.3	325.3	1.9
² H ₄ -DHEAS (IS)	GT	486.3	329.3	1.7
	<i>d</i> GT	489.3	329.3	1.7
	GP	506.3	329.3	1.9
	<i>d</i> GP	511.3	329.3	1.9

a. The parenthesized values are the t_{RS} of the minor isomers that were not used for the quantification.

Table 2 Matrix effects

Steroid	Derivative	Matrix effect ^a (%)
TS	GT	96.2 ± 5.4
	dGT	97.7 ± 4.9
	GP	93.6 ± 5.0
	dGP	95.4 ± 4.7
DHEAS	GT	89.2 ± 4.1
	dGT	88.6 ± 4.0
	GP	90.3 ± 4.0
	dGP	88.5 ± 3.9

a. The derivatized TS or DHEAS in the matrix sample / those in the standard sample × 100 (%). Mean ± SD (*n* = 5).

Table 3 Calibration curves for sample-quadruplex method

Steroid	Derivative	Slope ^a	y-intercept ^b	r^2	Measured concentration at lowest calibration point ^c
TS	GT	0.1251 ± 0.0021 , 1.7%	0.0042	≥ 0.997	0.399 ± 0.023 ng mL ⁻¹ , 5.8%
	dGT	0.1237 ± 0.0027 , 2.2%	0.0029	≥ 0.995	0.395 ± 0.031 ng mL ⁻¹ , 7.8%
	GP	0.1457 ± 0.0033 , 2.3%	0.0094	≥ 0.996	0.390 ± 0.047 ng mL ⁻¹ , 12.1%
	dGP	0.1324 ± 0.0024 , 1.8%	0.0051	≥ 0.998	0.404 ± 0.015 ng mL ⁻¹ , 3.7%
DHEAS	GT	0.3581 ± 0.0061 , 1.7%	0.0121	≥ 0.997	0.244 ± 0.023 µg mL ⁻¹ , 9.4%
	dGT	0.3556 ± 0.0072 , 2.0%	0.0013	≥ 0.998	0.238 ± 0.018 µg mL ⁻¹ , 7.6%
	GP	0.3249 ± 0.0062 , 1.9%	0.0190	≥ 0.995	0.238 ± 0.028 µg mL ⁻¹ , 11.8%
	dGP	0.3350 ± 0.0077 , 2.3%	0.0060	≥ 0.995	0.245 ± 0.021 µg mL ⁻¹ , 8.6%

a. Mean $\pm$ SD ($n = 5$) and RSD (%).

b. Mean ($n = 5$).

c. The samples containing 0.40 ng mL⁻¹ of TS and 0.25 µg mL⁻¹ of DHEAS (the lowest concentrations on the calibration curves) were measured five times. The results are expressed as the mean $\pm$ SD and RSD (%).

Figure captions

Fig. 1. Derivatization scheme of TS and DHEAS with Girard reagents. D = ^2H

Fig. 2. Chromatograms of TS, DHEAS and their ISs in four different serum samples after derivatization using four Girard reagents. A batch consisting of four serum samples was analyzed in a single run by the quadruplex method. For the derivatized TSs, the slower-eluting isomers marked with asterisks were used for the quantification. The measured concentrations were 3.98 (sample #1), 3.14 (#2), 4.66 (#3) and 3.15 ng mL^{-1} (#4) for TS, and 1.25 (sample #1), 3.54 (#2), 2.91 (#3) and 1.73 $\mu\text{g mL}^{-1}$ (#4) for DHEAS.

Fig. 1

Fig. 2

Graphical Index